Clinical Trials
Below are current clinical trials.
260 studies in Pulmonary and Critical Care Medicine Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of United States patients with chronic thromboembolic pulmonary hypertension through shared information, education, and collaborative investigation among pulmonary hypertension centers throughout the U.S.
-
Rochester, Minn.
The purpose of this clinical study is to assess the safety and effectiveness of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
-
Jacksonville, Fla.
The purpose of this study is to determine if anterior cervical discectomy and fusion surgery result in a higher incidence of obstructive sleep apnea.
-
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness of inhaled molgramostim, administered open-label, to adult cystic fibrosis subjects with chronic pulmonary nontuberculous mycobacterial (NTM) infection, with or without ongoing antimycobacterial guideline based combination therapy.
-
Rochester, Minn.
The purpose of this study is to correlate BAL CD8+ TRM cells and quantitative lung fibrosis scores in survivors of moderate-to-severe COVID-19 infection.
-
Rochester, Minn.
The purpose of this study is to evaluate Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).
-
Scottsdale/Phoenix, Ariz.
This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune response against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor.
-
Rochester, Minn.
The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.
-
Rochester, Minn.
The purpose of this study is to evaluate for safety and effectiveness weekly, open-label doses of levosimendan over extended use in patients with pulmonary hypertension with heart failure and preserved left ventricular ejection fraction (PH-HFpEF).
-
Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The purpose of this study is assess the pharmacodynamics, pharmacokinetics, safety and effectiveness of two different doses of Tocilizumab (TCZ) in combination with Standard of Care (SOC) in hospitalized adult patients with moderate-to-severe COVID-19 pneumonia.